How many insider trades does FilingIQ track for IDXG?

FilingIQ tracks 59 Form 4 insider transactions for IDXG (INTERPACE BIOSCIENCES, INC.), covering filings from Dec 28, 2015 onwards. 13 of those were filed in the last 90 days.

Are IDXG insiders net buyers or net sellers?

Across the full Form 4 history for IDXG, 9 transactions (15%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does IDXG insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is IDXG in?

INTERPACE BIOSCIENCES, INC. (IDXG) is classified in the Healthcare sector, specifically Diagnostics & Research, with a current market capitalisation of $51.24M.

IDXG insider trading

OTC Markets OTCPK Healthcare

INTERPACE BIOSCIENCES, INC. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

15% / 0%

Market cap

$51.24M

About INTERPACE BIOSCIENCES, INC.

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test for the diagnosis of pancreaticobiliary cancers using its proprietary PathFinderTG platform; PanDNA, a molecular only version of PancraGEN; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. The company also provides ThyraMIR v2, which assesses thyroid nodules for malignancy risk using a proprietary microRNA gene expression classifier; and RespriDx, a genomic test that enables physicians to differentiate metastatic or recurrent lung cancer. It primarily serves physicians, cancer centers, clinics, laboratories, pathology groups, and hospitals. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

Company website: www.interpace.com

IDXG insider activity at a glance

FilingIQ has scored 59 insider transactions for IDXG since Dec 28, 2015. The most recent filing in our index is dated Aug 20, 2026.

Across the full history, 9 open-market purchases and 0 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on IDXG insider trades is 43.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live IDXG trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 983

UNITED THERAPEUTICS Corp

NUVL 195

Nuvalent, Inc.

KYMR 193

Kymera Therapeutics, Inc.

GH 192

Guardant Health, Inc.

Hims & Hers Health, Inc.

Frequently asked

How many insider trades does FilingIQ track for IDXG?: FilingIQ tracks 59 Form 4 insider transactions for IDXG (INTERPACE BIOSCIENCES, INC.), covering filings from Dec 28, 2015 onwards. 13 of those were filed in the last 90 days.
Are IDXG insiders net buyers or net sellers?: Across the full Form 4 history for IDXG, 9 transactions (15%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does IDXG insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is IDXG in?: INTERPACE BIOSCIENCES, INC. (IDXG) is classified in the Healthcare sector, specifically Diagnostics & Research, with a current market capitalisation of $51.24M.

Methodology & sources

Every IDXG insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.